GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (OTCPK:SEELQ) » Definitions » Days Payable

SEELQ (Seelos Therapeutics) Days Payable : 0.00 (As of Jun. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Seelos Therapeutics Days Payable?

Seelos Therapeutics's average Accounts Payable for the three months ended in Jun. 2024 was $15.48 Mil. Seelos Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2024 was $0.00 Mil.

The historical rank and industry rank for Seelos Therapeutics's Days Payable or its related term are showing as below:

During the past 13 years, Seelos Therapeutics's highest Days Payable was 482.97. The lowest was 355.06. And the median was 419.02.

SEELQ's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 122.89
* Ranked among companies with meaningful Days Payable only.

Seelos Therapeutics's Days Payable stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00). stayed the same


Seelos Therapeutics Days Payable Historical Data

The historical data trend for Seelos Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seelos Therapeutics Days Payable Chart

Seelos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Seelos Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Seelos Therapeutics's Days Payable

For the Biotechnology subindustry, Seelos Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seelos Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's Days Payable falls into.


;
;

Seelos Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Seelos Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (3.626 + 16.403) / 2 ) / 0*365
=10.0145 / 0*365
=N/A

Seelos Therapeutics's Days Payable for the quarter that ended in Jun. 2024 is calculated as:

Days Payable (Q: Jun. 2024 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Mar. 2024 ) + Accounts Payable (Q: Jun. 2024 )) / count ) / Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=( (15.268 + 15.686) / 2 ) / 0*365 / 4
=15.477 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Seelos Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Seelos Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Seelos Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
Executives
Raj Mehra director, officer: See Remarks C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Michael Joseph Golembiewski officer: Chief Financial Officer 7 TURTLE CT, FLEMINGTON NJ 08822
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Judith Dunn director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Brian Lian director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Neil Morton officer: SVP, Chief Business Officer C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Richard W Pascoe director, officer: CEO & Secretary C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Sarissa Capital Domestic Fund Lp 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830